Glioma Clinical Trials in San Francisco, California

5 studies are recruiting for glioma in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Assessing Brain Metabolism Using MRS With Deuterated Glucose

   This study will investigate the use of Hydrogen 1 (1H) magnetic resonance spectroscopy (MRS) with deuterated glucose (2H-glucose) to detect dynamic glucose uptake in the brain.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT06594315 on ClinicalTrials.gov

2. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

   This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of California, San Francisco, California

   Locations

   61 in total

   Run by

   Nuvation Bio Inc.

   See if you can join NCT05303519 on ClinicalTrials.gov

3. Hyperpolarized Imaging in Diagnosing Participants With Glioma

   This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.

   Stage

   Phase 1

   Ages

   19 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   Susan Chang

   See if you can join NCT03739411 on ClinicalTrials.gov

4. A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

   This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment opti…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   23 in total

   Run by

   Nested Therapeutics, Inc

   See if you can join NCT06326411 on ClinicalTrials.gov

5. ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

   This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline radiotherapy will extend overall survival and progression-fr…

   Stage

   Phase 3

   Ages

   Any age

   Site

   UCSF Benioff Children's Hospital, San Francisco, California

   Locations

   162 in total

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT05580562 on ClinicalTrials.gov